Role of arbudahara tablet in patients with cancer

Clinical evaluation of Arbudahara tablet as palliative care management in arbuda wsr to carcinoma - Nil

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/10/096382

Enrollment

Registered

2025-10-23

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C801- Malignant (primary) neoplasm, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1 patients with signs and symptoms of carcinoma like abnormal lump or area of thickening that can be felt under the skin unintentional weight loss unexplained bleeding or bruising fatigue 2 patients diagnosed as carcinoma after histopathological report or being submitted for radiotherapy or chemotherapy or both 3 Controlled cases of Hypertension diabetes mellitus 4 TNM criteria T1toT3 N1toN3 M0 5 Post surgical case

Exclusion criteria

Exclusion criteria: 1 Metastasis T4M1 stage 2 Patients suffering from severe systemic disorders and diseases like HIV HbsAg STD TB etc 3 Uncontrolled DM Hypertension serious renal diseases hyperthyroidism

Design outcomes

Primary

Measure	Time frame
The study will improve quality of life of cancer patients Reduced the adverse effects of radiotherapy and reducing symptoms in carcinoma patientsTimepoint: 8 week	—

Secondary

Measure	Time frame
The study will improve quality of life of cancer patients Reduced the adverse effects of radiotherapy and reducing symptoms in carcinoma patientsTimepoint: 10 week	—

Countries

India

Contacts

Public ContactDrvipul sangani

Government Akhandananda Ayurved College and Hospital

drvipulvsangani@gmail.com9998960732

Outcome results